Observational study. Participants of the FRASNET study (9th March 2017, Protocol No. 24/INT/2017) who were evaluated in 2016 and 2017 will be contacted to be re-evaluated with multidimensional visits as part of the present study in order to assess trajectories and biomarkers of frailty and sarcopenia. Moreover, are going to evaluate with the same multidimensional visits patients with mild cognitive impairment and dementia followed up at the Neurologic Unit of the San Raffaele Hospital.
Study Type
OBSERVATIONAL
Enrollment
500
The sub-investigator performs a multidimentional geriatric evaluation
San Raffaele Hospital
Milan, Italy
RECRUITINGidentify new molecular markers of frailty and sarcopenia
To identify new molecular markers of frailty and sarcopenia in elderly volunteers and patients suffering from mild cognitive impairment and dementia assay of biomarkers (HMGB1, sRAGE, FGF21, GFD15 and neurofilaments)
Time frame: febbrary 2026
evaluate the ability of new markers for frailty, sarcopenia, cognitive impairment
To evaluate the ability of new markers (identified through the analysis of biobanked blood samples) to predict individual trajectories of frailty, sarcopenia, cognitive impairment and clinical outcomes assay of biomarkers (HMGB1, sRAGE, FGF21, GFD15 and neurofilaments)
Time frame: april 2026
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.